Skip to main content

Cytomegalovirus Infection

9
Pipeline Programs
10
Companies
18
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
7
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
850%
RNA Therapeutic
744%
Gene Therapy
16%
+ 6 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
3 programs
3
LetermovirPhase 3Small Molecule1 trial
LetermovirPhase 3Small Molecule1 trial
Letermovir tabletPhase 31 trial
Active Trials
NCT05763823Completed120Est. Apr 2024
NCT03930615Completed220Est. Mar 2022
NCT04129398Completed22Est. Oct 2022
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
3
LetermovirPhase 3Small Molecule
LetermovirPhase 3Small Molecule
Letermovir tabletPhase 3
Medica Corp
Medica CorpMA - Bedford
2 programs
1
1
Adoptive Cellular TherapyPhase 31 trial
CMV-specific T-cells, single infusion following single positive CMV PCR resultPhase 21 trial
Active Trials
NCT01220895Completed52Est. Jan 2014
NCT01077908Completed89Est. Oct 2014
Atara Biotherapeutics
Atara BiotherapeuticsCA - Thousand Oaks
1 program
1
CMV-pp65-specific cytotoxic T lymphocytesPhase 2
Moderna
ModernaCAMBRIDGE, MA
7 programs
mRNA-1647PHASE_1RNA Therapeutic1 trial
mRNA-1647PHASE_1RNA Therapeutic1 trial
mRNA-1647PHASE_2RNA Therapeutic1 trial
mRNA-1647PHASE_2RNA Therapeutic1 trial
mRNA-1647PHASE_2RNA Therapeutic1 trial
+2 more programs
Active Trials
NCT05105048Completed9Est. Aug 2023
NCT03382405Completed181Est. Oct 2020
NCT04232280Completed315Est. Jan 2023
+4 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
3 programs
Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus InfectionN/AGene Therapy1 trial
DBS Self-Collection KitN/A1 trial
ValganciclovirPHASE_4Small Molecule1 trial
Active Trials
NCT00001976Completed180Est. Feb 2003
NCT03910478Completed622Est. Jan 2024
NCT01552369Completed205Est. Jun 2018
Genentech
GenentechCA - Oceanside
1 program
ValganciclovirN/ASmall Molecule1 trial
Active Trials
NCT00374686Completed120Est. Sep 2005
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
BrincidofovirPHASE_2Small Molecule1 trial
Active Trials
NCT00942305Completed239Est. Jan 2012
Takeda
TakedaTOKYO, Japan
1 program
MaribavirPHASE_2Small Molecule1 trial
Active Trials
NCT00223925Completed111Est. Apr 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Allergy TherapeuticsValganciclovir
MSDLetermovir
ModernamRNA-1647
MSDLetermovir tablet
MSDLetermovir
Medica CorpAdoptive Cellular Therapy
ModernamRNA-1647
ModernamRNA-1647
ModernamRNA-1647
ModernamRNA-1647
Medica CorpCMV-specific T-cells, single infusion following single positive CMV PCR result
Jazz PharmaceuticalsBrincidofovir
TakedaMaribavir
ModernamRNA-1647
ModernamRNA-1647

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 10,298 patients across 18 trials

NCT01552369Allergy TherapeuticsValganciclovir

CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")

Start: Oct 2012Est. completion: Jun 2018205 patients
Phase 4Completed
NCT05763823MSDLetermovir

A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

Start: Mar 2023Est. completion: Apr 2024120 patients
Phase 3Completed
NCT05085366ModernamRNA-1647

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Start: Oct 2021Est. completion: Nov 20257,454 patients
Phase 3Terminated
NCT04129398MSDLetermovir tablet

MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

Start: Dec 2019Est. completion: Oct 202222 patients
Phase 3Completed
NCT03930615MSDLetermovir

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

Start: Jun 2019Est. completion: Mar 2022220 patients
Phase 3Completed
NCT01077908Medica CorpAdoptive Cellular Therapy

Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study

Start: Jul 2008Est. completion: Oct 201489 patients
Phase 3Completed
NCT06133010ModernamRNA-1647

A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Start: Feb 2024Est. completion: Dec 20270
Phase 2Withdrawn
NCT05683457ModernamRNA-1647

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Start: Apr 2023Est. completion: Aug 2026224 patients
Phase 2Recruiting
NCT04975893ModernamRNA-1647

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Start: Jun 2021Est. completion: Jan 2026135 patients
Phase 2Completed
NCT04232280ModernamRNA-1647

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

Start: Jan 2020Est. completion: Jan 2023315 patients
Phase 2Completed
NCT01220895Medica CorpCMV-specific T-cells, single infusion following single positive CMV PCR result

Alternate Donor Study of Pre-Emptive Cellular Therapy

Start: Oct 2010Est. completion: Jan 201452 patients
Phase 2Completed
NCT00942305Jazz PharmaceuticalsBrincidofovir

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

Start: Oct 2009Est. completion: Jan 2012239 patients
Phase 2Completed
NCT00223925TakedaMaribavir

Maribavir for Prevention of CMV After Stem Cell Transplants

Start: Oct 2004Est. completion: Apr 2006111 patients
Phase 2Completed
NCT05105048ModernamRNA-1647

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

Start: Nov 2021Est. completion: Aug 20239 patients
Phase 1Completed
NCT03382405ModernamRNA-1647

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

Start: Nov 2017Est. completion: Oct 2020181 patients
Phase 1Completed
NCT03910478Allergy TherapeuticsDBS Self-Collection Kit

Dried Blood Spot Testing of CMV Detection in HCT Recipients

Start: May 2019Est. completion: Jan 2024622 patients
N/ACompleted
NCT00374686GenentechValganciclovir

Study of Prophylactic Vs Preemptive Valganciclovir

Start: Mar 2003Est. completion: Sep 2005120 patients
N/ACompleted
NCT00001976Allergy TherapeuticsComparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection

Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection

Start: Jan 2000Est. completion: Feb 2003180 patients
N/ACompleted

Related Jobs

Research Associate, Infectious Disease Virology

ModernaModerna
Cambridge, Massachusetts; Research
2w ago
$63K - $101K/yr

Manager, Statistical Programming

ModernaModerna
Bethesda, Maryland; Clinical Development
3w ago
$109K - $175K/yr

Senior Research Associate, Virology

ModernaModerna
Cambridge, Massachusetts; Research
1mo ago
$74K - $118K/yr

2026 Co-Op, Infectious Disease Research

ModernaModerna
Cambridge, Massachusetts
1mo ago
$42K - $125K/yr

Sr. Regional Sales Manager, Vaccines, Region Nord (m/w/d)

ModernaModerna
Remote
1mo ago

Sr. Regional Sales Manager, Vaccines, Region West (m/w/d)

ModernaModerna
Remote
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 10,298 patients
Small Molecule is the dominant modality (50% of programs)
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.